

## **CURRENT REPORT 13/2024**

**March 27, 2024**

### **Ryvu project recommended for funding by the Polish Agency for Enterprise Development**

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company") informs that on March 25, 2024, it received an information about the inclusion by the Polish Agency for Enterprise Development ("PARP") of the Company's project against the negative assessment of the Company's project under the name "ONCO Prime: new possibilities for personalised anticancer therapy based on patient-derived primary cell cultures, omics characterisation and functional assays" ("Project") and the inclusion by PARP of the Company's Project on the updated list of projects recommended for funding under the SMART Track 1<sup>st</sup> call 2023 FENG.01.01-IP.02-001/23/2023, after the completed appeal procedure.

The ONCO Prime Project is a significant component in the implementation of the Company's plans in the early pipeline projects. The construction of a new platform for the discovery of innovative therapeutic targets using the unique patient-derived primary cancer cell cultures will open up entirely new possibilities for identifying new and unique protein targets enriching Ryvu's early-stage oncology portfolio, molecular classification of patients, and drug testing within the framework of the Company's existing projects. The ONCO Prime platform will become a source of innovative cancer models with the highest translational potential containing disease history, histopathological, genomic and transcriptomic data. Additionally, it will enable the correlation of clinical and molecular data, supporting the identification of patients sensitive to therapies developed by Ryvu.

- the total value of the Project (qualified costs): PLN 39 176 251.50;
- recommended amount of the funding for the Project: PLN 26 339 315.38;
- start of the Project implementation: May 2023;
- maximum Project duration: 56 months.

In case the funding agreement is concluded and the Project is implemented, the granted funding may limit the use of the Company's own funds.

The Company will announce the conclusion of the relevant funding agreement with PARP, as well as other significant events related to the Project, in the form of current reports.

*Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.*

**Legal basis:** Article 17.1 of MAR

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board